BL
BIO icon

Balentine LLC’s Bio-Rad Laboratories Class A BIO Stock Holding History

Balentine LLC’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-482
Closed -$239K – 615
2022
Q2 		$239K Buy
+482
New +$251K 0.01% 492
2020
Q3 		– Sell
-23
Closed -$10K – 232
2020
Q2 		$10K Buy
23
+4
+21% +$1.76K ﹤0.01% 550
2020
Q1 		$7K Buy
+19
New +$6.99K ﹤0.01% 420
2019
Q3 		– Sell
-6
Closed -$2K – 746
2019
Q2 		$2K Buy
+6
New +$1.8K ﹤0.01% 613
2018
Q1 		– Sell
-12
Closed -$3K – 115
2017
Q4 		$3K Hold
12
– – ﹤0.01% 556
2017
Q3 		$3K Hold
12
– – ﹤0.01% 557
2017
Q2 		$3K Hold
12
– – ﹤0.01% 527
2017
Q1 		$2K Buy
+12
New +$2.31K ﹤0.01% 541

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Balentine LLC's BIO Position: Q3 2022 in Review

Balentine LLC sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 482 shares — an estimated $239K sold.

Balentine LLC first reported a position in BIO in Q1 2017 and held it in 8 quarters. The position peaked at $239K in Q2 2022. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Balentine LLC reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Balentine LLC sold 482 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $239K.
  • Balentine LLC first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 8 quarters.
  • Balentine LLC's Bio-Rad Laboratories Class A position peaked at $239K in Q2 2022.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Balentine LLC's 13F filing for Q3 2022, filed 26 Oct 2022.